Κατευθυντήριες Οδηγίες
-
Κατεβάστε σε μορφή pdf τις Αναθεωρημένες Κατευθυντήριες Οδηγίες της Ευρωπαικής Εταιρίας Υπέρτασης - 2009. -
American Heart Association Learn and Live 2009 STEMI and PCI Focused Update
Με την ευγενική χορηγία:
- Home
- Our Society
- News
-
Publications
- 2009 Guidelines
- 2007 Guidelines
- Hypertension Guidelines
-
Studies
- 24hours Blood Pressure
- CHARM benefit regardless ACE dose
- Exercise Exaggerated BP Response
- STAR Study
- Trophy Study
- Controled Clinical Trials
- Blood Pressure Reduction
- Is New-Onset Diabetes of Clinical Significance in Treated Patients?
- ARAMIS Study
- Messages from Treatment Trials
- CAMELOT: Study Design
- INVEST
- Overview ACTION
- Medicines
-
Metabolic Syndrome
- MCEX-Nagel - Telmisartan
- Presioni Arteriose Monitorate
- Insulin Sensitizing Effects of Telmisartan
- New Treatment Strategies
- Treating the metabolic syndrome
- Antidiabetic mechanisms
- Ramipril vs Telmisartan
- Angiotensin Type 1 Receptor Blockers
- Telmisartan: PPARγ Activation & Metabolic Effects
- PPAR Ligands: Potential Therapies
- Metabolic Syndrome and type 2 diabetes mellitus
- Tsai Y-S 2004
- Όργανα Στόχοι
-
Cardiovascular Disease
- Action HF paper
- McMurrey AHJ
- Remaining Issues
- Telmi vs Valsa
- A cure for Cardiovascular disease?
- A Strategy to reduce cardiovascular disease
- Polypill for Cardiovascular Disease Prevention
- Polypill to fight cardiovascular disease
- Polypill to fight cardiovascular disease - Response
- Poly-Portfolio
- Take forward the polypill idea
- The Polymeal
- Polypill - Not for primary prevention
- PPRAγ Roberts AW
- Other
- Scientific Material
- Online Registration
- Contact
LogicONE